Detail of the clinical trial
| Title of the trial | A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses |
|---|---|
| EudraCT number | 2014-001617-12 |
| Protocol number | AP24534-14-203 |
| Sponsor | ARIAD Pharmaceuticals, Inc., (a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited), 40 Landsdowne Street, Cambridge, MA 02139 , United States of America |
| Indications | Hemato-oncology |
| Diagnosis | Chronic Myeloid Leukemia |
| Population in clinical trial |
Adults (18-65 years) Elderly ( > 65 years) Male Female Patients |
| Year of receiving the request to Institute (SÚKL) | 2015 |
| Date of approval by Institute (SÚKL) | 5.10.2015 |
| Date of approval by EC | 24.8.2015 |
| Date of initiation CT in ČR | |
| Date of ending CT in ČR | 18.7.2018 |
| Notice | |
| Sites | Fakultní nemocnice Olomouc,,I.P. Pavlova 6,Olomouc,775 20 |
cz